Adbiotech

(주)애드바이오텍 · KOSDAQ · 179530 · Industry: Manufacture of animal medicaments

Key metrics

Earnings

Revenue, Q3 2026₩7.2bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+146.3% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY+97.3% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026-₩1.2bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+40.1% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+34.0% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩12.3bn As of Oct 30, 2026 Source 1 ↗, Source 2 ↗, Source 3
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months12,386,505 shares As of Oct 30, 2026 Source 1 ↗, Source 2 ↗, Source 3, Source 4 ↗
Potential new shares, % of shares104.4% As of Oct 30, 2026 Source 1 ↗, Source 2 ↗, Source 3, Source 4 ↗, Source 5 ↗
Conversion price adjustments, last 12 months1 As of Jan 26, 2026 Source 1 ↗

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months17 As of Nov 19, 2026
DART filings, previous 3 months38 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)1,000 shares As of Dec 10, 2025 Source 1 ↗
Open-market buys, last 12 months (amount)₩0 As of Nov 19, 2026
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)1,000 shares As of Dec 10, 2025 Source 1 ↗
Insiders who bought, last 12 months1 As of Dec 10, 2025 Source 1 ↗

Insider transactions (last 12 months)

Open-market buys: 1,000 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: +1,000 shares. Insiders who bought: 1.

Trade dateInsider (role)TypeSharesPriceAmount
Jun 5, 2026Bikeipateuneoseu Tujajohap 1ho (10%+ shareholder)Other (Third-party placement)+5,987,774 shares₩1,824₩10.9bn
Jan 19, 2026Jeong Hong Geol (Registered director)Other (OTC buy)+174,603 shares——
Jan 14, 2026Bikeipateuneoseu Tujajohap2ho (10%+ shareholder)Other (Third-party placement)+3,319,251 shares₩1,657₩5.5bn
Dec 10, 2025Kim Dong-hyeon (Registered director)Open-market buy+1,000 shares——
Nov 20, 2025Bikeipateuneoseutujajohap1ho (10%+ shareholder)Other (Third-party placement)+3,407,863 shares₩1,657₩5.6bn

Annual financials

YearRevenueOperating income
2025₩12.9bn-₩3.5bn
2024₩11.1bn-₩4.1bn
2023₩10.5bn-₩4.8bn

Filing timeline